Bausch + Lomb (BLCO) – Investment Analysts’ Weekly Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Bausch + Lomb (NYSE: BLCO) in the last few weeks:

• 10/31/2024 – Bausch + Lomb had its price target raised by analysts at Wells Fargo & Company from $23.00 to $26.00. They now have an “overweight” rating on the stock.
• 10/31/2024 – Bausch + Lomb had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 10/31/2024 – Bausch + Lomb had its price target raised by analysts at Citigroup Inc. from $20.00 to $24.00. They now have a “buy” rating on the stock.
• 10/31/2024 – Bausch + Lomb had its price target raised by analysts at HC Wainwright from $22.00 to $23.00. They now have a “buy” rating on the stock.
• 10/22/2024 – Bausch + Lomb had its price target raised by analysts at Royal Bank of Canada from $20.00 to $23.00. They now have an “outperform” rating on the stock.
• 10/15/2024 – Bausch + Lomb was upgraded by analysts at Evercore ISI from an “in-line” rating to an “outperform” rating. They now have a $25.00 price target on the stock, up previously from $19.00.
• 10/1/2024 – Bausch + Lomb had its price target raised by analysts at Evercore ISI from $17.00 to $19.00. They now have an “in-line” rating on the stock.
• 9/23/2024 – Bausch + Lomb had its price target raised by analysts at Stifel Nicolaus from $16.00 to $19.00. They now have a “hold” rating on the stock.
• 9/23/2024 – Bausch + Lomb had its price target raised by analysts at HC Wainwright from $19.00 to $22.00. They now have a “buy” rating on the stock.
• 9/16/2024 – Bausch + Lomb had its “hold” rating reaffirmed by analysts at Needham & Company LLC.

Bausch + Lomb Trading Up 0.1 %

Bausch + Lomb stock traded up $0.01 during midday trading on Tuesday, reaching $19.88. The stock had a trading volume of 677,710 shares, compared to its average volume of 571,892. The stock has a market capitalization of $7.00 billion, a PE ratio of -18.93, a price-to-earnings-growth ratio of 1.93 and a beta of 0.46. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.95 and a current ratio of 1.57. The stock’s 50-day simple moving average is $18.68 and its 200 day simple moving average is $16.52. Bausch + Lomb Co. has a twelve month low of $13.16 and a twelve month high of $21.69.

Bausch + Lomb (NYSE:BLCO) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.16 by $0.01. The company had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $1.17 billion. Bausch + Lomb had a negative net margin of 7.86% and a positive return on equity of 3.17%. Bausch + Lomb’s revenue for the quarter was up 18.8% on a year-over-year basis. During the same quarter last year, the company earned $0.22 earnings per share. Analysts expect that Bausch + Lomb Co. will post 0.59 EPS for the current year.

Institutional Trading of Bausch + Lomb

Several institutional investors have recently added to or reduced their stakes in the business. Fore Capital LLC acquired a new position in Bausch + Lomb during the 1st quarter valued at approximately $384,000. Gabelli Funds LLC boosted its position in Bausch + Lomb by 3.3% during the 1st quarter. Gabelli Funds LLC now owns 312,000 shares of the company’s stock worth $5,398,000 after acquiring an additional 10,000 shares during the period. Whitebox Advisors LLC grew its stake in shares of Bausch + Lomb by 29.3% in the first quarter. Whitebox Advisors LLC now owns 1,206,303 shares of the company’s stock worth $20,869,000 after purchasing an additional 273,484 shares in the last quarter. Invenomic Capital Management LP acquired a new position in shares of Bausch + Lomb during the first quarter valued at $6,817,000. Finally, Rokos Capital Management LLP bought a new position in Bausch + Lomb in the 1st quarter valued at about $5,602,000. Institutional investors own 11.07% of the company’s stock.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.